Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.

Jones SA, Murakami E, Delaney W, Furman P, Hu J.

Antimicrob Agents Chemother. 2013 Sep;57(9):4181-9. doi: 10.1128/AAC.00599-13. Epub 2013 Jun 17. Erratum in: Antimicrob Agents Chemother. 2013 Nov;57(11):5788.

2.

Hepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.

Clark DN, Hu J.

Antiviral Res. 2015 Nov;123:132-7. doi: 10.1016/j.antiviral.2015.09.011. Epub 2015 Sep 25. Review.

4.

A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.

Karatayli E, Karayalçin S, Karaaslan H, Kayhan H, Türkyilmaz AR, Sahin F, Yurdaydin C, Bozdayi AM.

Antivir Ther. 2007;12(5):761-8.

PMID:
17713159
5.
6.

Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.

Niu C, Bao H, Tolstykh T, Micolochick Steuer HM, Murakami E, Korba B, Furman PA.

Antivir Ther. 2010;15(3):401-12. doi: 10.3851/IMP1541.

PMID:
20516559
7.

Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.

Walsh AW, Langley DR, Colonno RJ, Tenney DJ.

PLoS One. 2010 Feb 12;5(2):e9195. doi: 10.1371/journal.pone.0009195.

8.

Inhibition of reverse transcriptase activity of hepatitis B virus polymerase by β-l-D4A-TP.

Wang XY, Gao LL, Hu ZH, Wang HL, Deng F, Jin JS.

Acta Virol. 2008;52(1):47-52.

PMID:
18459835
9.

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

Seifer M, Hamatake RK, Colonno RJ, Standring DN.

Antimicrob Agents Chemother. 1998 Dec;42(12):3200-8.

10.

Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction.

Xu X, Thai H, Kitrinos KM, Xia G, Gaggar A, Paulson M, Ganova-Raeva L, Khudyakov Y, Lara J.

BMC Bioinformatics. 2016 Aug 31;17 Suppl 8:280. doi: 10.1186/s12859-016-1116-4.

12.

Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance.

Menéndez-Arias L, Álvarez M, Pacheco B.

Curr Opin Virol. 2014 Oct;8:1-9. doi: 10.1016/j.coviro.2014.04.005. Epub 2014 May 9. Review.

PMID:
24814823
13.

Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.

Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES, Shin GC, Kim KH.

J Virol. 2010 May;84(9):4494-503. doi: 10.1128/JVI.02066-09. Epub 2010 Feb 17.

15.

Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery.

Rhee SY, Margeridon-Thermet S, Nguyen MH, Liu TF, Kagan RM, Beggel B, Verheyen J, Kaiser R, Shafer RW.

Antiviral Res. 2010 Dec;88(3):269-75. doi: 10.1016/j.antiviral.2010.09.012. Epub 2010 Sep 25.

16.
17.

Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.

van Hemert FJ, Berkhout B, Zaaijer HL.

PLoS One. 2014 Sep 2;9(9):e106324. doi: 10.1371/journal.pone.0106324. eCollection 2014.

18.

Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents.

Iyer RP, Jin Y, Roland A, Morrey JD, Mounir S, Korba B.

Antimicrob Agents Chemother. 2004 Jun;48(6):2199-205.

19.
20.

Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.

Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW.

Antimicrob Agents Chemother. 2007 Jan;51(1):48-53. Epub 2006 Nov 6.

Supplemental Content

Support Center